399 BINNEY STREET, CAMBRIDGE, MA
Announces Data from Zovegalisib + Fulvestrant at the Phase 3 Dose of 400mg BID Fed at ESMO Targeted Anticancer Therapies Congress 2026
Relay Therapeutics Amends Bylaws to Designate Exclusive Forum
Reports Fourth Quarter and Full Year 2025 Financial Results and Outlines Anticipated 2026 Milestones
Zovegalisib Granted Breakthrough Therapy Designation by U.S. FDA for PIK3CA-mutant, HR+/HER2- Advanced Breast Cancer
Reports Third Quarter 2025 Financial Results and Corporate Updates
Reports Second Quarter 2025 Financial Results and Corporate Updates
Changes in Board, Management or Compensation
Shareholder votes
FY 2024
Q3
Q2
Q1
FY 2023
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Notice of Exempt Offering of Securities
Definitive Proxy Statement
Additional Proxy Materials
Amended Schedule 13G - Ownership Report
Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Prospectus filed pursuant to Rule 424(b)(7)